Schizophrenics win NHS drugs battle
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
More than 200,000 people with schizophrenia could benefit from newer, more expensive drugs after campaigners won a 10-year battle yesterday to end rationing.
In a ruling hailed as a victory for people with severe mental illness, the NHS's drugs advisory body, the National Institute for Clinical Excellence, said "atypical" antipsychotics should be much more widely available, especially for newly diagnosed schizophrenia.
The newer drugs have fewer side-effects than the older antipsychotics, but because atypicals cost £1,220 per person a year compared with £70 for the older drugs, charities say patients in many areas have been denied the treatment.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments